Newsroom In the US, use of the Mitra device is limited to research and non-diagnostic applications. In many countries outside the US, the Mitra device can be used as a sample collection device for clinical diagnostic applications, as referenced in some content.

Quanterix Publishes Study Paper on High-Sensitivity SARS-CoV-2 Test

by Neoteryx, on April 22,2021

At the end of March 2021, Quanterix Corporation issued a press release announcing that its Simoa® technology had been used in a research study to detect the SARS-CoV-2 virus. According to the company, Simoa uses both bead and well technology to perform a type of digital immunoassay blended with standard analogue detection for high-sensitivity quantitation across a wide concentration range. The SARS-CoV-2 study used serum/plasma samples, dried blood microsamples and saliva samples obtained from polymerase chain reaction (PCR)+ COVID-19 patients to test for direct antigen and also raised antibodies. Mitra® devices based on VAMS® technology from Neoteryx were used for the dried blood microsampling component of the research study.

Published in Nature Communications, the research study paper is titled "N-protein presents early in blood, dried blood and saliva during asymptomatic and symptomatic SARS-CoV-2 infection." The paper illustrates that non-invasive antigen detection using blood or saliva samples, including samples collected from asymptomatic and pre-symptomatic individuals, can augment testing of nasopharyngeal (NP) swab samples.

In their news announcement, Quanterix stated that their test can detect SARS-CoV-2 viral infection during the pre-symptomatic window when transmissibility is known to be highest. Their test method can also measure viral load in blood, which can be an indicator of disease severity or progression, and potentially of therapeutic efficacy.

As quoted in the news release and related articles, Kevin Hrusovsky, Chairman, CEO and President of Quanterix and Founder of Powering Precision Health (PPH) stated, “While vaccine deployment continues at an aggressive pace, COVID-19 testing and clinical research tools will remain a global priority in the months to come." Hrusovsky added that sensitive measurements of viral antigen and the adaptive immune response from sample types suitable for remote collection could help facilitate global public health efforts to curtail viral spread while accelerating therapy development in clinical research programs.

The news announcement reiterated that current PCR-based testing remains the gold standard for COVID-19 detection, but it also stated that concerns have been raised with respect to false negative results associated with NP swabs. According to data published in the Annals of Internal Medicine, on the fifth day of infection – the median time for symptom onset and the peak of viral transmission – molecular tests show a 38% probability of producing a false result. The announcement from Quanterix also highlighted how PCR-based supply chains have been strained by increased testing demands. 

The company stated that increased testing demands require additional testing options. They report that their Simoa HD-X Analyzer™ has the high-sensitivity and specificity needed to quantitate the SARS-CoV-2 nucleocapsid protein and anti-SARS-CoV-2 spike IgG directly in the various sample matrices used in their research study. Their test is reportedly authorized for use with NP swabs, but not yet authorized by the FDA for emergency use with saliva or dried blood microsamples.

According to the research team, they observed a more than 90% positive percentage agreement (PPA) of COVID-19 positive patients and a more than 98% negative percent agreement (NPA) in all matrices within seven days of a positive PCR test. They used sample cohorts that included both asymptomatic and symptomatic individuals. The research team also demonstrated an inverse correlation between nucleocapsid protein clearance and an increase in SARS-CoV-2 anti-spike IgG in all matrices. This suggests that an early and robust IgG response mitigates severe disease outcomes, even when high levels of viral nucleocapsid protein are initially present.

“With technologies like Simoa, which can measure the concentration of viral proteins in blood and saliva samples obtained non-invasively, new pathways may become available to expand access to accurate and reliable testing, and to extend our understanding of COVID-19 biology," Hrusovsky stated in the company's news release. 

The results presented in the Nature Communications publication were obtained using Research Use Only (RUO) assays from Quanterix. Visit the company's COVID-19 web page for details on Simoa assays that received EUA. 

This is curated content. To learn more about Quanterix’ technology, visit the Quanterix Website

For information on conducting COVID-19 research, click below:

infectious disease resource bundle

Topics:COVID-19COVID-19 testsSARS-CoV-2

Comments

The latest product releases, company news and microsampling industry updates from Neoteryx.

search our newsroom

news reporter resources:

If you don’t find the information & assets you need via the buttons below, please contact us here: press@neoteryx.com

Fact Sheet & FAQs

social media

subscribe to news